# Elkedonia

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/elkedonia

- Industry: Biotechnology
- Headquarters: Strasbourg, France
- Website: www.elkedonia.com
- Total disclosed funding: $13M
- Latest round: Seed (Jun 11, 2025)
- Investors on record: 8

## About

Based in France, Elkodonia SAS specializes in developing innovative medical treatments focused on antidepressants that promote neuroplasticity, differentiating their approach from traditional therapies for improved mental health outcomes.Elkodonia SAS, founded in 2025 and headquartered in Strasbourg, France, is dedicated to producing antidepressants emphasizing neuroplasticity. The company raised EUR 11.25 mn in Seed funding on June 11, 2025, co-led by Kurma Partners, WE Life Sciences, and Bpifrance Investissement, among other investors. This funding will support their biotechnology research and development efforts.Elkodonia develops innovative antidepressant treatments centered on neuroplasticity. Their flagship product is a neuroplastogen that aims to induce neuroplasticity, thereby reducing side effects common with traditional antidepressants and psychedelics. These products target a wide demographic, including teenagers and children, addressing a gap where approximately 35% of patients do not respond to existing treatments, with a focus on North America, Europe, and parts of Asia.Elkodonia’s revenue primarily comes from partnerships and collaborations in the pharmaceutical and healthcare sectors, involving business-to-business transactions with healthcare providers and research institutions. Their typical transaction model includes licensing agreements and collaborative research initiatives that integrate their neuroplastogen into clinical trials and treatment protocols. Specific pricing models have not been disclosed.Following the recent EUR 11.25 mn Seed funding raised on June 11, 2025, Elkodonia plans to utilize this capital to enhance its biotechnology research and development. The company is focused on expanding its product offerings and aims to penetrate new markets where mental health disorders are prevalent. They are particularly targeting North America, Europe, and parts of Asia as key regions for growth.

## Funding rounds

- Seed, Jun 11, 2025, $13M — Kurma Partners, Sambrinvest, Bpifrance Investissement, Capital Grand Est, Argobio SAS, CARMA FUND Management, Angelini Ventures, WE Life Sciences

## Investors

- Kurma Partners (https://capitalatlas.ai/funds/kurma-partners) — Seed
- Sambrinvest (https://capitalatlas.ai/funds/sambrinvest) — Seed
- Bpifrance Investissement (https://capitalatlas.ai/funds/bpifrance-investissement) — Seed
- Capital Grand Est (https://capitalatlas.ai/funds/capital-grand-est) — Seed
- Argobio SAS — Seed
- CARMA FUND Management (https://capitalatlas.ai/funds/carma-fund-management) — Seed
- Angelini Ventures (https://capitalatlas.ai/funds/angelini-ventures) — Seed
- WE Life Sciences — Seed